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Abstract
Pegylated-interferon plus ribavirin (PEG-IFN/RBV) therapy is a current standard treatment for chronic hepatitis C. We
previously reported that the viral sequence heterogeneity of part of NS5A, referred to as the IFN/RBV resistance-determining
region (IRRDR), and a mutation at position 70 of the core protein of hepatitis C virus genotype 1b (HCV-1b) are significantly
correlated with the outcome of PEG-IFN/RBV treatment. Here, we aimed to investigate the impact of viral genetic variations
within the NS5A and core regions of other genotypes, HCV-2a and HCV-2b, on PEG-IFN/RBV treatment outcome.
Pretreatment sequences of NS5A and core regions were analyzed in 112 patients infected with HCV-2a or HCV-2b, who were
treated with PEG-IFN/RBV for 24 weeks and followed up for another 24 weeks. The results demonstrated that HCV-2a
isolates with 4 or more mutations in IRRDR (IRRDR[2a]$4) was significantly associated with rapid virological response at
week 4 (RVR) and sustained virological response (SVR). Also, another region of NS5A that corresponds to part of the IFN
sensitivity-determining region (ISDR) plus its carboxy-flanking region, which we referred to as ISDR/+C[2a], was significantly
associated with SVR in patients infected with HCV-2a. Multivariate analysis revealed that IRRDR[2a]$4 was the only
independent predictive factor for SVR. As for HCV-2b infection, an N-terminal half of IRRDR having two or more mutations
(IRRDR[2b]/N$2) was significantly associated with RVR, but not with SVR. No significant correlation was observed between
core protein polymorphism and PEG-IFN/RBV treatment outcome in HCV-2a or HCV-2b infection. Conclusion: The present
results suggest that sequence heterogeneity of NS5A of HCV-2a (IRRDR[2a]$4 and ISDR/+C[2a]), and that of HCV-2b
(IRRDR[2b]/N$2) to a lesser extent, is involved in determining the viral sensitivity to PEG-IFN/RBV therapy.
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Introduction
Hepatitis C virus (HCV) is a major cause of chronic liver disease,
such as chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma, with180 million people being currently infected with
HCV worldwide. It is estimated that 70% of acute infections
become persistent [1]. As a consequence of the long-term
persistence of HCV infection, the number of patients with
hepatocellular carcinoma is expected to increase further over the
next 20 years. More than two decades have passed since the
discovery of HCV, and yet therapeutic options remain limited.
Standard regimens for treatment of chronic hepatitis C include
pegylated interferon alpha (PEG-IFN) and ribavirin (RBV) [2]. In
addition, two protease inhibitors (telaprevir and boceprevir) were
approved in May 2011 by the U. S. Food and Drug Administration
(FDA) for clinical use in combination with PEG-IFN/RBV to treat
chronic hepatitis C patients with HCV genotype 1 [3,4].
In Japan, about 70% of HCV-infected patients are infected with
HCV genotype 1b (HCV-1b) and most of the remaining patients
are infected with HCV-2a (25%) or HCV-2b (5%) [5]. When
treated with PEG-IFN/RBV, the sustained virological response
(SVR) rate is ca. 50% in HCV-1b infection, and ca. 80% in HCV-
2a and -2b infections [2,6]. The mechanism(s) underlying the
different responses among patients with different HCV genotypes
and subtypes is still unclear. However, this suggests that viral
genetic heterogeneity could affect, at least to some extent, the
sensitivity to IFN-based therapy. In this context, sequence
heterogeneity of the viral NS5A protein has been widely discussed
for its correlation with IFN responsiveness. Sequence variations
within a region in NS5A of HCV-1b defined as the IFN sensitivity-
determining region (ISDR) is correlated with IFN responsiveness
[7]. In HCV-2a infection, the influence of sequence heterogeneity
in and around a region corresponding to ISDR on the IFN
responsiveness was also suggested [8–10]. Recently, we identified a
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30513new region near the C-terminus of NS5A of HCV-1b, which we
refer to as the IFN/RBV resistance-determining region (IRRDR)
[11,12]. The degree of sequence variation within IRRDR was
significantly correlated with the clinical outcome of PEG-IFN/
RBV combination therapy. The significance of IRRDR of other
HCV genotypes, however, has not been investigated yet.
In addition to the NS5A sequence variation, HCV core protein
polymorphism was also proposed as a pretreatment predictor of
poor virological response in HCV-1b-infected patients treated
with PEG-IFN/RBV therapy [13]. It is not clear at this stage
whether core protein polymorphism could be used to predict the
treatment outcome in HCV-2a and -2b infections. In the present
study, we investigated the impact of viral genetic heterogeneity in
the NS5A and core regions of HCV-2a and -2b on PEG-IFN/
RBV treatment outcome. To the best of our knowledge, this is the
first report describing the possible correlation between PEG-IFN/
RBV responsiveness and NS5A-IRRDR heterogeneity of HCV-2a
and -2b.
Materials and Methods
Ethics statement
The study protocol, which conforms to the provisions of the
Declaration of Helsinki, was approved beforehand by the Ethic
Committees in Kobe Asahi Hospital and Kobe University, and
written informed consent was obtained from each patient prior to
the treatment.
Patients
A total of 112 patients seen at Kobe Asahi Hospital and Kobe
University Hospital, Kobe, Japan, who were chronically infected
with HCV-2a (61 patients) or HCV-2b (51 patients), were enrolled
in the study. HCV subtype was determined according to the
method of Okamoto et al. [14]. The patients were treated with
PEG-IFN a-2b (PegintronH; Schering-Plough, Kenilworth, NJ)
(1.5 mg per kilogram body weight, once weekly, subcutaneously)
and RBV (RebetolH; Schering-Plough) (600,800 mg daily, per
os), for 24 weeks according to a standard treatment protocol for
Japanese patients established by a hepatitis study group of the
Ministry of Health, Labour and Welfare, Japan. All patients
received .80% of scheduled dosage of PEG-IFN and RBV.
Serum samples were collected from the patients at intervals of 4
weeks before, during and after the treatment, and tested for HCV
RNA and core antigen titers as reported previously [15].
Sequence analysis of the NS5A and core regions
HCV RNA was extracted from 140 ml of serum using a
commercially available kit (QIAmp viral RNA kit; QIAGEN,
Tokyo, Japan). The extracted RNA was reverse transcribed and
amplified for NS5A and core regions using Super script III one
step RT-PCR platinum Taq HiFi (Invitrogen, Tokyo, Japan). The
resultant RT-PCR product was subjected to a second-round PCR
by using Platinum Taq DNA polymerase high fidelity III
(Invitrogen). Primers used for amplification of full-length NS5A
of the HCV-2a and -2b genomes and those of the core region of
HCV-2a were reported previously [16,17]. Primers for amplifica-
tion of the core region of HCV-2b are as follows: C-2b/1 (59-
AGCCATAGTGGTCTGCGGAACC-39; sense, nucleotides [nt]
136 to 157) and C-2b/4 (59-GGAACARTTGCACTCTTGG-
GTG-39; antisense, nt 1241 to 1262) for one step RT-PCR; C-2b/
2( 5 9-CCACTCTATGTCCGGTCATTTGG-39; sense, nt 208 to
230) and C-2b/3 (59-GAGCTGCCAGGTGATGCTG-39; anti-
sense, nt 971 to 989) for the second round PCR. RT was
performed at 45uC for 30 min and terminated at 94uC for 2 min,
followed by the first-round PCR over 35 cycles, with each cycle
consisting of denaturation at 94uC for 30 sec, annealing at 55uC
for 30 sec and extension at 68uC for 90 sec. The second-round
PCR was performed under the same condition. The sequences of
the amplified fragments were determined by direct sequencing
without subcloning. The amino acid (aa) sequences were deduced
and aligned using GENETYX Win software version 7.0
(GENETYX Corp., Tokyo, Japan). The numbering of aa residues
for HCV-2a and -2b isolates is according to the polyprotein of
HCV-J6 [18] and -J8 [19], respectively.
Statistical analysis
Numerical data were analyzed by Student’s t test while
categorical data by Fisher’s exact probability test [8]. To evaluate
the optimal threshold of the number of aa mutations in ISDR and
IRRDR for prediction of treatment outcomes, the receiver
operating characteristic curve was constructed. Univariate and
multivariate logistic regression analyses were performed to identify
independent predictors for treatment outcomes. All statistical
analyses were performed using the SPSS version 16 software
(SPSS Inc., Chicago, IL). Unless otherwise stated, a P value of
,0.05 was considered statistically significant.
Nucleotide sequence accession numbers
The sequence data reported in this paper have been deposited
in the DDBJ/EMBL/GenBank nucleotide sequence databases
with the accession numbers AB600751 through AB600834.
Results
Patients’ Responses to PEG-IFN/RBV Combination
Therapy in HCV-2a and HCV-2b infections
Of the 61 patients infected with HCV-2a, 46 (75%) patients
cleared HCV viremia by week 4 (rapid virological response
[RVR]), and all the patients (100%) by week 12 (early virological
response [EVR]) and at week 24 (end-of-treatment response
[ETR]) (Table 1). Likewise, of 51 patients infected with HCV-2b,
34 (67%), 51 (100%) and 50 (98%) patients achieved RVR, EVR
and ETR, respectively. After the end of treatment, 105 patients (58
with HCV-2a and 47 with HCV-2b) could be followed up for
another 24 weeks. At the end, SVR was achieved by 49 (84%)
patients infected with HCV-2a and by 34 (72%) patients with
HCV-2b. Only 9 (16%) and 13 (28%) patients with HCV-2a and -
2b, respectively, were non-SVR. There was no case of null-
response (continuous viremia throughout the treatment and follow
up periods) since all the non-SVR patients once cleared viremia at
a certain time point followed by a rebound in viremia either before
or after the end of the treatment (relapse).
Comparison of the base line demographic characteristics
between SVR and non-SVR patients revealed that, in HCV-2a
infection, SVR patients had a significantly lower average age than
that of non-SVR (Table 2). In HCV-2b infection, on the other
hand, SVR patients had significantly c-GTP levels than those of
non-SVR. There was no significant difference in viremia titers
between SVR and non-SVR in patients infected with HCV-2a or -
2b.
Sequence Analysis of NS5A of HCV-2a and HCV-2b
The entire NS5A region of the HCV-2a and -2b genomes in
pretreatment sera were sequenced, and aa sequences deduced. All
the sequences obtained were aligned and the consensus sequences
for HCV-2a and -2b were inferred. An N-terminal half (aa 1977 to
2196) of the consensus sequences of HCV-2a and -2b isolates were
each identical to the prototype sequences, HCV-J6 [18] and
NS5A-IRRDR of HCV-2a/2b and PEG-IFN/RBV
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2197 to 2442) of the consensus sequences were identical to those
reported by Murakami et al. [8] except that His at position 2358 in
the HCV-2b sequence was replaced with Cys, which was more
conserved (59% of the isolates tested) than His (22%).
To investigate the impact of NS5A heterogeneity on the clinical
outcome of PEG-IFN/RBV therapy, we first performed a sliding
window analysis with a window size of 20 residues over the full-
length NS5A sequences obtained from 23 RVR and 7 non-RVR
patients infected with HCV-2a along with the consensus sequence,
as described previously [8]. This analysis revealed that the number
of aa mutations differed significantly between RVR and non-RVR
isolates in two regions within the C-terminal half of NS5A (data
not shown). The more C-terminally located one exactly matched
the region that corresponded to IRRDR of HCV-1b, ranging
from aa 2332 to 2387, thus being referred to as IRRDR[2a] (see
Figure 1). The other region composed of a part of ISDR plus its
carboxy-flanking region, ranging from aa 2232 to 2262, thus being
referred to as ISDR/+C[2a] (see Figure 2). It was confirmed that
the average numbers of aa mutations in IRRDR[2a] and ISDR/
+C[2a] were each significantly larger in isolates from RVR than
those from non-RVR patients (Table 3). More importantly, the
average numbers of aa mutations in IRRDR[2a] and ISDR/
+C[2a] were each significantly larger in SVR than in non-SVR.
Sequences of IRRDR[2a] and ISDR/+C[2a] obtained from SVR
and non-SVR patients and the number of mutations of each
isolate are shown in Figures 1 and 2.
Likewise, a sliding window analysis on HCV-2b isolates (16
RVR and 6 non-RVR) identified an N-terminal part of IRRDR
(aa 2332 to 2357), referred to as IRRDR/N[2b], that showed a
significant difference in the number of aa mutations between RVR
and non-RVR (data not shown). The average numbers of aa
mutations in IRRDR/N[2b] were significantly larger in RVR
than in non-RVR (Table 3). However, they did not differ
significantly between SVR and non-SVR. Sequences of
IRRDR[2b]/N obtained from RVR and non-RVR patients are
shown in Figure 3.
Correlation between NS5A Sequence Heterogeneity and
SVR or RVR in HCV-2a and HCV-2b infections
The receiver operating characteristic analysis identified the
optimal thresholds of the numbers of aa mutations in IRRDR[2a]
and ISDR/+C[2a] for the prediction of RVR and SVR in HCV-
2a infection; four and one for IRRDR[2a] and ISDR/+C[2a],
respectively (data not shown). Accordingly, we found that 86%
(42/49) of SVR patients, and only 22% (2/9) of non-SVR, were
infected with HCV-2a isolates having IRRDR with 4 or more
mutations (IRRDR[2a]$4) (Table 4). On the other hand, 14% (7/
49) of SVR, and 78% (7/9) of non-SVR patients, were infected
with isolates having IRRDR with 3 or less mutations (IRR-
DR[2a]#3). These results suggested that IRRDR[2a]$4 was
significantly associated with SVR (P=0.0003). Similarly, 93%
(42/46) of RVR patients, and only 33% (5/15) of non-RVR, were
infected with HCV-2a isolates of IRRDR[2a]$4 while 7% (4/46)
of RVR patients, and 67% (10/15) of non-RVR, were infected
with HCV-2a isolates of IRRDR[2a]#3, with the results
suggesting that IRRDR[2a]$4 was significantly associated with
RVR as well (P,0.0001).
As for ISDR/+C[2a] heterogeneity, 71% (35/49) of SVR, and
22% (2/9) of the non-SVR patients, were infected with HCV-2a
isolates with ISDR/+C having one or more mutation (ISDR/
+C[2a]$1) (Table 4). On the other hand, 29% (14/49) of SVR
patients, and 78% (7/9) of the non-SVR, were infected with
isolates with ISDR/+C without mutation (ISDR/+C[2a]=0).
Thus, ISDR/+C[2a]$1 was significantly associated with SVR
(P=0.008).
Table 1. Proportions of various virological responses of HCV-
2a- and HCV-2b-infected patients treated with PEG-IFN/RBV.
Response Proportion
HCV-2a HCV-2b All
RVR 46/61* (75%) 34/51 (67%) 80/112 (71%)
Non-RVR 15/61 (25%) 17/51 (33%) 32/112 (29%)
EVR 61/61 (100%) 51/51 (100%) 112/112 (100%)
ETR 61/61 (100%) 50/51 (98%) 111/112 (99%)
SVR 49/58 (84%) 34/47 (72%) 83/105 (79%)
Non-SVR 9/58 (16%) 13/47 (28%) 22/105 (21%)
*No. of patients/no. of total.
Abbreviations: RVR, rapid virological response; EVR, early virological response;
ETR, end-of-treatment response; SVR, sustained virological response.
doi:10.1371/journal.pone.0030513.t001
Table 2. Demographic characteristics of HCV-2a- and HCV-2b-infected patients with SVR and non-SVR.
Factor HCV-2a HCV-2b
SVR Non-SVR P value SVR Non-SVR P value
Age 49.78613.67* 62.8967.01 0.007 50.03615.03 55.08611.22 0.28
Sex (male/female) 22/27 3/6 0.72 17/17 8/5 0.53
Body weight (kg) 60.39611.00 54.67610.51 0.15 57.72613.46 65.0867.26 0.06
Platelets (610
4/mm
3)1 8 . 5 4 65.71 19.43610.78 0.72 17.5765.65 15.2067.281 0.27
Hemoglobin (g/dl) 14.3866.07 14.061.56 0.88 14.1961.59 13.7861.5 0.49
c-GTP (IU/L) 37.66653.25 36.83624.82 0.97 39.68634.33 81.30669.11 0.02
ALT (IU/L) 64.75652.45 94.386141.3 0.28 86.35691.95 86.856118.7 0.98
HCV-RNA (KIU/ml) 135061424 159861464 0.63 554367643 7905614210 0.47
HCV core antigen (fmol/L) 654366927 610568290 0.91 905466743 939068723 0.92
*Mean 6 S.D.
Abbreviations: SVR, sustained virological response; c-GTP, gamma glutamyl transpeptidase; ALT, alanine aminotransferase.
doi:10.1371/journal.pone.0030513.t002
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analysis identified ‘‘two’’ as the optimal threshold of the number of
mutations in IRRDR/N[2b] by which to predict RVR (data not
shown). Accordingly, we found that 65% (22/34) of RVR, and
18% (3/17) of non-RVR patients, were infected with HCV-2b
isolates of IRRDR/N[2b]$2 (Table 4). On the other hand, 35%
(12/34) of RVR, and 82% (14/17) of the non-RVR patients, were
infected with IRRDR/N[2b]#1. These results suggested that
IRRDR/N[2b]$2 was significantly associated with RVR
(P=0.0025). However, no correlation, or even no tendency
toward significant correlation, was observed between IRRDR/
N[2b]$2 and SVR in HCV-2b infection.
Correlation between NS5A Sequence Heterogeneity and
Viremia Titers in the Serum of patients infected with
HCV-2a and HCV-2b before PEG-IFN/RBV Therapy
Next, we examined the impact of IRRDR sequence
heterogeneity on HCV titers in the serum before the initiation
of the treatment. As shown in Figure 4A, patients infected with
IRRDR[2a]$4 had significantly lower pretreatment serum
Figure 1. Sequence alignment of IRRDR[2a]. Sequences of IRRDR[2a] (interferon/ribavirin resistance-determining region of HCV-2a) obtained
from SVR and non-SVR patients are aligned. The consensus sequence (Cons) is shown on the top. The numbers along the sequence indicate the aa
positions. Dots indicate residues identical to those of the Cons sequence. The numbers of the mutations in IRRDR[2a] are shown on the right.
doi:10.1371/journal.pone.0030513.g001
NS5A-IRRDR of HCV-2a/2b and PEG-IFN/RBV
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DR[2a]#3. On the other hand, there was no significant
difference in HCV viremia titers between ISDR/+C[2a]$1
and ISDR/+C[2a]=0 (Figure 4B). Also, in HCV-2b infection,
there was no significant difference in pretreatment HCV viremia
titers between IRRDR/N[2b]$2 and IRRDR/N[2b]#1
(Figure 4C).
Correlation between Core Protein Sequence
Heterogeneity and RVR or SVR
A close correlation between core protein sequence patterns and
treatment outcome has been proposed in HCV-1b infection
[12,13]. To examine this hypothesis in HCV-2a and -2b
infections, core regions of the virus genome were amplified from
the pretreated sera, and the aa sequences deduced and aligned
Figure 2. Sequence alignment of ISDR/+C[2a]. Sequences of ISDR/+C[2a] (part of interferon sensitivity determining-region plus its carboxy-
flanking region of HCV-2a) obtained from SVR and non-SVR patients are aligned. The consensus sequence (Cons) is shown on the top. The numbers
along the sequence indicate the aa positions. Dots indicate residues identical to those of the Cons sequence. The numbers of the mutations in ISDR/
+C[2a] are shown on the right.
doi:10.1371/journal.pone.0030513.g002
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treated sera of HCV-2a and -2b-infected patients with SVR, non-SVR, RVR and non-RVR.
NS5A region No. of mutations No. of mutations
SVR Non-SVR P value RVR Non-RVR P value
IRRDR[2a] (aa 2332–2387) 6.463.4* 3.362.1 0.01 6.863.3 3.361.9 0.0003
ISDR/+C[2a] (aa 2232–2262) 2.062.4 0.360.7 0.047 2.162.5 0.660.7 0.025
IRRDR/N[2b] (aa 2332–2357) 1.861.5 1.461.3 0.45 2.061.4 1.061.2 0.01
*Mean 6 S.D.
Abbreviations: SVR, sustained virological response; RVR, rapid virological response; IRRDR[2a], interferon/ribavirin resistance-determining region of HCV-2a; ISDR/+C[2a],
part of interferon sensitivity determining-region plus its carboxy-flanking region of HCV-2a; IRRDR/N[2b], an N-terminal part of interferon/ribavirin resistance-
determining region of HCV-2b.
doi:10.1371/journal.pone.0030513.t003
Figure 3. Sequence alignment of NS5A of HCV-2b isolates. Sequences of IRRDR/N[2b] (an N-terminal part of interferon/ribavirin resistance-
determining region of HCV-2b) obtained from RVR and non-RVR patients are aligned. The consensus sequence (Cons) is shown on the top. The
numbers along the sequence indicate the aa positions. Dots indicate residues identical to those of the Cons sequence. The numbers of the mutations
in IRRDR/N[2b] and the final treatment outcome of each patient are shown on the right.
doi:10.1371/journal.pone.0030513.g003
NS5A-IRRDR of HCV-2a/2b and PEG-IFN/RBV
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The residues at positions 70 and 91, which were reported to be
associated with the treatment outcome in HCV-1b infection [13],
were both well conserved among HCV-2a and -2b isolates and,
therefore, no correlation with treatment outcome was expected for
these residues (Figures S1 and S2). In this connection, the residues
at positions 48 and 110 of HCV-2a isolates showed certain degrees
of variation. However, there was no significant correlation
between the sequence patterns and the treatment outcome.
Identification of Independent Predictive Factors for SVR
and RVR in HCV-2a and HCV-2b infections
In order to identify significant independent predictors of SVR in
HCV-2a and HCV-2b infections, univariate and multivariate
logistic regression analyses were carried out using all available data
of baseline patients’ parameters and viral genetic polymorphic
factors. Univariate analysis identified 3 factors that were
significantly associated with SVR in HCV-2a infection; the
heterogeneity of IRRDR[2a] ($4 vs. #3), ISDR/+C[2a] ($1
vs. =0) and patients’ age (,55 years) (Table 5). Subsequently,
these factors were entered in multivariate regression analysis. The
result obtained revealed that the IRRDR[2a] heterogeneity was
the only independent predictive factor for SVR in HCV-2a
infection (P=0.001). The IRRDR[2a] heterogeneity was also the
independent predictive factor for RVR (Table S1).
As for HCV-2b infection, univariate analysis identified two host
factors that were significantly, or almost significantly, associated
with SVR; c-GTP levels (,30 IU/L) and body weight (,65 kg)
(Table 5). No viral factor was identified in this analysis. In
subsequent multivariate analysis, c-GTP levels was identified as an
independent predictive factor for SVR in HCV-2b infection. In
this connection, the heterogeneity of IRRDR/N[2b], a viral
factor, was identified to be significantly associated with RVR in
HCV-2b infection (Table S1).
Discussion
The clinical outcome of PEG-IFN/RBV therapy for HCV
infection is influenced by a number of host and viral factors [20]. It
has recently been reported that host genetic polymorphisms near
or within the IL28B gene on the chromosome 19 show a critical
impact on the treatment outcome of patients infected with HCV-
1a and -1b [21–23]. Also, HCV genetic polymorphisms have been
known to contribute to differences in the treatment outcome, as
demonstrated by the observations that SVR rates for patients
infected with HCV genotypes 2 and 3 are higher than those for
patients infected with HCV genotype 1 [2,6]. Moreover,
Table 4. Correlation between NS5A sequence heterogeneity and SVR or RVR in HCV-2a and HCV-2b infections.
Factor SVR Non-SVR P value RVR Non-RVR P value
IRRDR[2a]$4 42/49* (86%) 2/9 (22%) 0.0003 42/46 (93%) 5/15 (33%) ,0.0001
IRRDR[2a]#3 7/49 (14%) 7/9 (78%) 4/46 (7%) 10/15 (67%)
ISDR/+C[2a]$1 35/49 (71%) 2/9 (22%) 0.008 32/46 (70%) 7/15 (47%) 0.1
ISDR/+C[2a]=0 14/49 (29%) 7/9 (78%) 14/46 (30%) 8/15 (53%)
IRRDR/N[2b]$2 17/34 (50%) 6/13 (46%) 1.0 22/34 (65%) 3/17 (18%) 0.0025
IRRDR/N[2b]#1 17/34 (50%) 7/13 (54%) 12/34 (35%) 14/17 (82%)
*No. of isolates with a given factor/total no. of SVR or RVR.
Abbreviations: SVR, sustained virological response; RVR, rapid virological response; IRRDR[2a], interferon/ribavirin resistance-determining region of HCV-2a; ISDR/+C[2a],
part of interferon sensitivity determining-region plus its carboxy-flanking region of HCV-2a; IRRDR/N[2b], an N-terminal part of interferon/ribavirin resistance-
determining region of HCV-2b.
doi:10.1371/journal.pone.0030513.t004
Figure 4. Correlation between NS5A sequence heterogeneity and pretreatment serum HCV core antigen titers in HCV-2a and HCV-
2b infections. Pretreatment serum HCV core antigen titers of patients classified on the basis of the number of mutations in IRRDR[2a] (interferon/
ribavirin resistance-determining region of HCV-2a) ($4 vs. #3) (A), ISDR/+C[2a] (part of interferon sensitivity determining-region plus its carboxy-
flanking region of HCV-2a) ($1 vs. =0) (B) and IRRDR/N[2b] ($2 vs. #1) (an N-terminal part of interferon/ribavirin resistance-determining region of
HCV-2b) (C) are depicted. Maximum and minimum values are indicated by the upper and lower bars, respectively. Distribution ranges are displayed
as boxes. Mean and median values are also indicated inside the boxes as+and horizontal bars, respectively.
doi:10.1371/journal.pone.0030513.g004
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genotype, in particular HCV-1b, have been linked to the
difference in SVR rates [7,8,11–13,17]. It should be noted that
the significant link between polymorphisms of NS5A and core
regions of HCV-1b and treatment outcome was inferred mostly
from studies carried out on patients in Asian countries, in
particular Japan, and that somewhat controversial results were
obtained from studies carried out on patients infected with HCV-
1a or -1b in non-Asian countries [24–31]. However, we would like
to point out that most of these publications focused mainly on
ISDR and core mutations, but not on IRRDR. In addition, the
impact of viral genetic variation on treatment outcome in non-
HCV-1 infection, either in Asian or non-Asian countries, is still
unclear.
In our previous study, we identified IRRDR in NS5A of HCV-
1b as a significant determinant for PEG-IFN/RBV treatment
outcome; EVR and, more importantly, SVR [11,12]. Consistent
with the previous observation, we have demonstrated in the
present study that sequence heterogeneity within IRRDR is closely
correlated with the treatment responses in HCV-2a and -2b
infections. In HCV-2a infection, IRRDR[2a]$4 was closely
associated with RVR (Table S1) and SVR (Table 5). In HCV-
2b infection, the sequence heterogeneity within an N-terminal part
of IRRDR (IRRDR/N[2b]) was significantly associated with
RVR (Table S1). Furthermore, both IRRDR[2a]$4 and ISDR/
+C[2a]$1 showed remarkable positive predictive values (95%) for
SVR prediction (Table S2), suggesting the clinical usefulness of
these markers to encourage those patients to receive PEG-IFN/
RBV treatment. On the other hand, their negative predictive
values for non-SVR were rather low (50% and 33%). This suggests
the possible involvement of another factor(s) that determines non-
SVR and may limit the clinical usefulness of these markers to
accurately predict non-SVR.
The present results were dependent upon the small number of
non-SVR patients due to the high response rates of HCV-2a and -
2b. In spite of this, the parallels between the RVR/non-RVR and
the SVR/non-SVR analyses, especially in HCV-2a infection,
support the possibility that the sequences presented in this study
are truly representative of the viruses in general circulation.
The clinical correlation between IRRDR sequence heteroge-
neity and virological responses of IFN-based therapy in HCV
infection can be linked to a recent experimental observation by
Tsai et al. [32] that an HCV subgenomic RNA replicon
containing NS5A of HCV-1b exerted more profound inhibitory
effects on IFN activities than the original HCV-2a replicon, and
that domain swapping between NS5A sequences of HCV-1b and -
2a in the V3 and/or a C-terminal region including IRRDR
resulted in a transfer of their anti-IFN activities. Also, it is worthy
to note that IRRDR is among the most variable sequences across
the different genotypes and subtypes of HCV [33] whereas its
upstream and downstream sequences show a higher degree of
sequence conservation (Figure 5). This may suggest that whereas
the upstream and downstream sequences have a conserved
function(s) across all the HCV genotypes, IRRDR sequences have
a genotype-dependent or even a strain-dependent function(s).
Indeed, the upstream sequences, especially a Pro-rich motif, play
key roles in multiple stages of viral replication [34] while the
downstream sequence in viral particle assembly and production
[35]. Therefore, the sequence heterogeneity of IRRDR and its
significant correlation with IFN-responsiveness imply the possibil-
ity that IRRDR is involved, at least partly, in the viral strategy to
evade IFN-mediated antiviral host defense mechanisms. Its
possible molecular mechanism, however, is yet to be elucidated.
The IRRDR sequence heterogeneity also suggests genetic
flexibility of this region and, indeed, the C-terminal portion of
NS5A was shown to tolerate sequence insertions and deletions
[36]. This flexibility might play an important role in modulating
the interaction with various host systems, including IFN-induced
antiviral machineries. It is also possible that the genetic flexibility
of IRRDR is accompanied by compensatory changes elsewhere in
the viral genome and that these compensatory changes affect
overall viral fitness and responses to IFN-based therapy [37].
The relapse rate was higher in HCV-2b infection than in HCV-
2a (Table 1). It should be noted that while the sequence
heterogeneity within IRRDR[2a] was significantly correlated with
both RVR and SVR in HCV-2a infection, IRRDR/N[2b] was
correlated only with RVR in HCV-2b infection. These observa-
tions might be linked to an intrinsic difference in IFN- and/or
RBV-sensitivity between HCV-2a and -2b isolates [8,38]. We
assume that HCV-2b is considered between HCV-1b and HCV-
2a in terms of resistance to PEG-IFN/RBV treatment and that an
extended treatment for a total of 36,48 weeks would be needed to
prevent relapse in HCV-2b infection, especially for patients who
have risk factors that do not fit the SVR or RVR prediction
criteria (Table 5 and Table S1).
A mutation at position 70 of the core protein of HCV-1b has
been reported to be correlated with PEG-IFN/RBV treatment
outcome [12,13]. In the present study, however, we found no
significant correlation between core protein polymorphism and
treatment outcome in HCV-2a or -2b infections. The residue at
position 70 of the core protein of HCV-2a and -2b isolates was
Arg, which is known to be associated with SVR in HCV-1b
infection [12,13], and was well conserved in all the isolates tested
in the present study (Figures S1 and S2). The observed sequence
Table 5. Univariate and multivariate analyses for identification of independent predictive factors for SVR in HCV-2a- and -2b-
infected patients treated with PEG-IFN/RBV therapy.
Genotype Variable Univariate Multivariate
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
HCV-2a IRRDR[2a] mutations 21.0 (3.6–122.5) 0.0003 21.0 (3.6–122.5) 0.001
ISDR/+C[2a] mutations 8.8 (1.6–47.4) 0.008
Age (,55 years) 9.8 (1.1–84.7) 0.026
HCV-2b c-GTP (,30 IU/L) 26.0 (1.3–504.7) 0.004 6.2 (1.1–36.2) 0.04
Body weight (,65 kg) 3.8 (1.0–13.9) 0.06
Abbreviations: SVR, sustained virological response; IRRDR[2a], interferon/ribavirin resistance-determining region of HCV-2a; ISDR/+C[2a], part of interferon sensitivity
determining-region plus its carboxy-flanking region of HCV-2a; c-GTP, gamma glutamyl transpeptidase.
doi:10.1371/journal.pone.0030513.t005
NS5A-IRRDR of HCV-2a/2b and PEG-IFN/RBV
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e30513conservation at position 70 might be the reason for the lack of
significant correlation between core protein polymorphism and
treatment outcome in HCV-2a or -2b infections. On the other
hand, Thr at position 110 of the core protein of HCV-2a has
recently been reported to be significantly associated with SVR
[10]. In the present study, Thr at position 110 was found in 35%
(14/40) and 14% (1/6) of SVR and non-SVR cases, respectively
(Figure S1). Similarly, Thr at position 48 was found in 35% (14/
40) of SVR cases, but not in non-SVR cases (0/6). The observed
differences between SVR and non-SVR, however, were not
statistically significant due possibly to the small number of samples
tested. A larger-scale study would be needed to determine the
possible importance of those residues.
We preliminarily analyzed a host genetic factor, the single
nucleotide polymorphism (SNP) at rs8099917 near the IL28B gene
[21–23], of a portion of the patients examined in the present study.
The result showed that the minor genotypes (T/G and G/G) were
found in 5.1% (2/39) and 15.4% (2/13) of RVR and non-RVR
patients, respectively, and 2.8% (1/36) and 20.0% (2/10) of SVR
and non-SVR patients, respectively (Kim et al., unpublished
observation). Although the differences were not statistically
significant due probably to the small number of the patients
tested, the minor genotypes showed a trend toward being
associated with non-SVR, and with non-RVR to a lesser extent,
in HCV-2a and -2b infections, as has been reported for HCV-1a
and -1b infections [21–23]. The impact of the IL28B SNP,
however, appeared to be weaker in HCV-2a and -2b infections
than that seen in HCV-1a and -1b infections, and also weaker
than that of the most powerful viral factor, IRRDR[2a]$4, in
HCV-2a infection. In this context, we found that, of the four
patients with the minor IL28B genotypes, two patients (nos. 2 and
105), who underwent unfavorable treatment response (non-RVR
and non-SVR), were infected with HCV isolates of IRR-
DR[2a]#3 or IRRDR/N[2b]#1 while the other two patients
(no. 63 and 106), who achieved favorable treatment response
(SVR and/or RVR), were infected with HCV isolates of
IRRDR[2a]$4. This might imply the possibility that, in HCV-2
infection, the combination of the minor IL28B genotypes and a
low degree of IRRDR sequence heterogeneity has a strong power
to predict unfavorable treatment responses whereas a high degree
of IRRDR sequence heterogeneity has a dominant predictive
power for favorable treatment responses regardless the IL28B
genotype. Analysis in a large-scale multicenter study is needed to
clarify this issue.
In conclusion, our data suggest that the sequence heterogeneity
of NS5A, i.e., IRRDR[2a]$4, and ISDR/+C[2a]$1 to a lesser
extent, would be a useful predictive marker for SVR in HCV-2a
infection. Also, IRRDR/N[2b]$2 is significantly associated with
RVR in HCV-2b infection. These results further emphasize the
importance of NS5A, a viral factor, in determining the
responsiveness to PEG-IFN/RBV therapy.
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Figure S1 Sequence alignment of the core protein of
HCV-2a isolates. Core protein sequences (aa 1 to 120) of HCV-
2a obtained from SVR and non-SVR patients are aligned.
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